KBC Group’s Syndax Pharmaceuticals SNDX Stock Holding History

KBC Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$58K	Hold	3,062	–	–	﹤0.01%	1680
2026 Q2	$67K	Hold	3,062	–	–	﹤0.01%	1611
2026 Q1	$72K	Sell	3,062 -2,118	-41%	-$46K	﹤0.01%	1498
2025 Q4	$109K	Hold	5,180	–	–	﹤0.01%	1220
2025 Q3	$80K	Hold	5,180	–	–	﹤0.01%	1401
2025 Q2	$49K	Hold	5,180	–	–	﹤0.01%	1617
2025 Q1	$64K	Sell	5,180 -1,774	-26%	-$25K	﹤0.01%	1716
2024 Q4	$92K	Buy	6,954 +3,559	+105%	+$60.9K	﹤0.01%	1617
2024 Q3	$65K	Hold	3,395	–	–	﹤0.01%	1577
2024 Q2	$70K	Buy	+3,395	New	+$71K	﹤0.01%	1420

Other funds holding SNDX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Vienna Insurance Group Warsaw, Poland $466M AUM 97.31% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

KBC Group's SNDX Position: Q3 2026 in Review

KBC Group held its Syndax Pharmaceuticals (SNDX) position steady in Q3 2026 at 3,062 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

KBC Group first reported a position in SNDX in Q2 2024 and has held it in 10 quarters since. The position peaked at $109K in Q4 2025. 76 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

KBC Group held 3,062 shares of Syndax Pharmaceuticals worth $58K as of Q3 2026.
KBC Group left its Syndax Pharmaceuticals share count unchanged in Q3 2026.
Syndax Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1680 holding.
KBC Group first reported a position in Syndax Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
KBC Group's Syndax Pharmaceuticals position peaked at $109K in Q4 2025.
76 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.